Vanda Pharmaceuticals, Inc. (VNDA)

More than a one trick pony.

Overbought. I see this stock settling down a buck or 2.

Rated one star.

Hm, is in talks to be bought.

Another one from UltraLong!

Aqcuisition or partnership

Plucked this from "UltraLong" who currently has a 98% accuracy rate. Holy Sh#% 98%?!?

This pharmaceutical has big spike on good news, but it's badly run and overvalued.

Thanks Ultralong for this, I love the chart!

Going Down?

VNDA

do to the mere fact of a potential billion dollar a year drug.

This stock will explode, I new atypical with less weight gain and less drowsiness, will be a highly used medication.

Greatly undervalued. A gamble that could either fizzle or be a 6-bagger. Not much on the downside, but a lot of potential upside.

Vanda Pharmaceuticals signs deal with Laboratory Corp. to sell genetic test

FDA approval of Fanapta will be decided on 7/27/08. There is no advisory panel for fanapta which is good news since advisory panel usually means theres some short comings. Overall research shows high chance of it being approved by the FDA and after that....caching

This stock is above it's 20- and 30-day moving average on the charts. They did not report any revenues for the end of last year and it is in the healthcare sector and the biotechnology and drugs industry. I have heard that the healthcare stocks are the ones to get into.

Vanda is expecting a decision on Fanapta, their schizophrenia drug, by late June. The drug performed well in Phase III clinical trials, with lower side effects than the presently prescribed drugs. Up until the decisoin is made, I think the buzz around this drug will push the stock price up over $6. It's a pretty risky play though, as this drug pretty much makes or breaks Vanda. Although their Q1 losses were less than expected, I don't think Vanda survives if Fanapta doesn't make it to market. But if it does, expect the stock to see a big jump in price. In the meantime, I think we'll see a steady creep upward as the hype around Fanapta grows.

As of close of business on 12/18/2007, this was a 5-star Morningstar stock trading at less than half it's Morningstar fair value.

I thought it was undervalued at $26 so I think it's really undervalued now. Two drugs, both with billion dollar indications, coming out of successful phase 3 trials. At least one of them should be approved by FDA. $105 million in cash, no debt. Bully!